Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial
Purpose: Numerous chemotherapeutic agents are cytotoxic through generation of reactive species, and variability in genes related to oxidative stress may influence disease-free survival (DFS). We examined relationships between DFS and variants in NOS3 , as well as NQO1, NQO2 , and CBR3 , among treate...
Saved in:
Published in | Clinical cancer research Vol. 15; no. 16; pp. 5258 - 5266 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.08.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: Numerous chemotherapeutic agents are cytotoxic through generation of reactive species, and variability in genes related to
oxidative stress may influence disease-free survival (DFS). We examined relationships between DFS and variants in NOS3 , as well as NQO1, NQO2 , and CBR3 , among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial (S8897).
Experimental Design: In the parent trial, women were assigned according to prognostic features; the high-risk group was randomized to cyclophosphamide,
i.v. methotrexate, and 5-fluorouracil or to cyclophosphamide, i.v. doxorubicin, and 5-fluorouracil ± tamoxifen, and the low-risk
group did not receive adjuvant therapy. We extracted DNA from normal lymph node tissue and examined functional polymorphisms
in NOS3, NQO1, NQO2 , and CBR3 , in relation to DFS, using Cox proportional hazard model.
Results: There were significant interactions between DFS, adjuvant therapy, and NOS3 Glu298Asp and −786 polymorphisms, alone and in combination ( P for interaction = 0.008). When NOS3 genotypes were combined, women with genotypes encoding for lower nitric oxide who received chemotherapy had a >2-fold increase
in hazard of progression (hazard ratio, 2.32; 95% confidence interval, 1.26-4.25), whereas there was reduced risk for those
who did not receive adjuvant therapy (hazard ratio, 0.42; 95% confidence interval, 0.19-0.95). There were no associations
between the other genotypes and DFS in either group.
Conclusion: Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status. These
results may mirror the known dual functions of nitric oxide and nitric oxide synthase, depending on oxidative environment.
(Clin Cancer Res 2009;15(16):5258–66) (Clin Cancer Res 2009;15(16):5258–) |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-09-0685 |